Desloratadine
A non-sedating second-generation antihistamine that is the active metabolite of loratadine, used for allergic rhinitis, chronic hives, and allergic skin conditions. It selectively blocks peripheral H1 histamine receptors with minimal CNS penetration.
الوزن الجزيئي
310,8000 g/mol
LogP
4,50
TPSA
24,90 Ų
قاعدة ليبينسكي للخمسة
ناجح
المجالات العلاجية
آلية العمل
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
البنية ثنائية الأبعاد
Cite this structure
Embed this structure
SMILES
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1
InChI
InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2
Molecular Formula
C19H19ClN2
HBD / HBA
1 / 2
الروابط القابلة للدوران
0
الذرات الثقيلة
22
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
الأسئلة الشائعة
A non-sedating second-generation antihistamine that is the active metabolite of loratadine, used for allergic rhinitis, chronic hives, and allergic skin conditions. It selectively blocks peripheral H1 histamine receptors with minimal CNS penetration.
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Yes, Desloratadine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1172. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 124087. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="desloratadine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/desloratadine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/desloratadine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/desloratadine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="desloratadine"></drugfyi-drug>